The peptide library
Every entry states its evidence level and approval status up front. Filter by what the research shows, not by what a product page claims.
ARA-290 (cibinetide)
An erythropoietin-derived peptide that targets tissue repair rather than red blood cells; small trials, mixed results, no approval.
Ecallantide
A recombinant plasma kallikrein inhibitor for acute hereditary angioedema attacks, given under medical supervision.
Enfuvirtide
The first HIV fusion inhibitor, an injected peptide that blocks the virus from entering cells.
Icatibant
A bradykinin receptor blocker given under the skin to abort hereditary angioedema attacks.
LL-37 (cathelicidin)
The body's own antimicrobial peptide, studied for wound healing and infection; a research compound, not a treatment.
Larazotide
A synthetic peptide designed to tighten the gut lining in coeliac disease. Promising in mid-stage trials, then failed its phase 3 primary endpoint.
Thymalin
A Russian thymus-extract peptide sold for immune support, with a literature that has never been independently replicated.
Thymosin alpha-1
A synthetic thymic peptide registered as a medicine in several countries and studied as an immune modulator in hepatitis and sepsis. Not approved in the US or EU.